ReviewFrontiers in cell and developmental biology2026
TXNL1 in redox and protein quality control: mechanisms and disease relevance.
Review in Frontiers in cell and developmental biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
TXNL1 (thioredoxin-like protein 1), a member of the thioredoxin superfamily, integrates thioredoxin oxidoreductase activity with molecular chaperone function. Through its N-terminal TRX domain and C-terminal PITH domain, TXNL1 not only helps maintain cellular redox homeostasis but also prevents toxic aggregation of oxidatively damaged proteins. Consequently, TXNL1 acts as a critical buffer in the cellular defense against oxidative stress and in protein quality control. TXNL1 is widely expressed across diverse tissues, and its dysregulation is closely associated with multiple pathological conditions, including chemotherapy resistance in gastric cancer, poor prognosis in colorectal cancer, arsenic-induced malignant transformation of bronchial epithelial cells, and ischemic as well as traumatic injuries of the central nervous system. TXNL1 undergoes degradation through both canonical ubiquitin-dependent and ubiquitin-independent mechanisms. This review summarizes the discovery, molecular architecture, expression patterns, physiological functions, and disease-related research progress of TXNL1, and discusses its potential clinical applications as a biomarker and therapeutic target.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.